CHMA News and Press, Chiasma Inc. From 09/25/19

WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer and Dr. William Ludlam, Sen...

A vote is like a rifle: its usefulness depends upon the character of the user ." - Theodore Roosevelt Today, we revisit a 'Busted IPO' we looked at back in the second half of 2018. The company has done a good job advancing its pipeline. A full investment analysis follows in the paragr...

WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, will host a Key Opinion Leader (KOL) breakfast on maintenance therapy of adult patie...

WALTHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer and Dr. William Ludlam, Sen...

Chiasma, Inc. (CHMA) Q2 2019 Results Conference Call August 8, 2019 5:00 PM ET Company Participants Glenn Garmont – Investor relations Raj Kannan – Chief Executive Officer Bill Ludlam – Senior Vice President-Clinical Development and Medical Affairs Mark Fit...

Chiasma (NASDAQ: CHMA ): Q2 GAAP EPS of -$0.25 beats by $0.04 . More news on: Chiasma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Announces positive data from Phase 3 CHIASMA OPTIMAL trial; MYCAPSSA ® NDA submission expected by year-end 2019 with an expected six-month PDUFA review time period MPOWERED enrollment complete; topline data expected in second half 2020 Completes common stock offering for n...

WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcast on Thursda...

Chiasma ( CHMA ) announced that it had achieved positive results in a Phase 3 study using octreotide capsules (Mycapssa) for treatment of adults with acromegaly. This positive Phase 3 data will allow the biotech to file an NDA for its drug candidate in this indication by the end of 2019,...

Chiasma Inc. ( CHMA ) shares rose over 30% recently, buoyed by favorable results from the Phase 3 clinical trial for its octreotide capsules, conditionally trade-named drug Mycapssa, for the maintenance treatment of adults with acromegaly. Acromegaly is a hormone disorder that typically de...